Literature DB >> 30964515

The Evolving Uses of "Real-World" Data.

Ethan Basch1,2, Deborah Schrag2,3.   

Abstract

Mesh：

Year:  2019        PMID： 30964515     DOI： 10.1001/jama.2019.4064

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  16 in total

1.  Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy.

Authors:  Janet Sultana; Francesco Trotta; Antonio Addis; Jeffrey S Brown; Miguel Gil; Francesca Menniti-Ippolito; Federica Milozzi; Samy Suissa; Gianluca Trifirò
Journal:  Drug Saf       Date:  2020-01       Impact factor: 5.606

2.  What is Evidence-Based Functional Medicine in the 21st Century?

Authors:  Jeffrey S Bland
Journal:  Integr Med (Encinitas)       Date:  2019-06

3.  Precision reimbursement for precision medicine: the need for patient-level decisions between payers, providers and pharmaceutical companies.

Authors:  Sanjay Budhdeo; Michael Ruhl; Paul M Agapow; Nikhil Sharma; Parker Moss
Journal:  Future Healthc J       Date:  2021-11

Review 4.  Toward a better understanding about real-world evidence.

Authors:  Mei Liu; Yana Qi; Wen Wang; Xin Sun
Journal:  Eur J Hosp Pharm       Date:  2021-12-02

Review 5.  Methodological Issues in Analyzing Real-World Longitudinal Occupational Health Data: A Useful Guide to Approaching the Topic.

Authors:  Rémi Colin-Chevalier; Frédéric Dutheil; Sébastien Cambier; Samuel Dewavrin; Thomas Cornet; Julien Steven Baker; Bruno Pereira
Journal:  Int J Environ Res Public Health       Date:  2022-06-08       Impact factor: 4.614

6.  Patient-reported outcomes collected in ambulatory oncology practices: Feasibility, patterns, and correlates.

Authors:  Christopher R Friese; Alex J Fauer; Clare Kuisell; Kari Mendelsohn-Victor; Nathan C Wright; Jennifer J Griggs; Milisa Manojlovich
Journal:  Health Serv Res       Date:  2020-10-30       Impact factor: 3.402

7.  Natural Language Processing to Ascertain Cancer Outcomes From Medical Oncologist Notes.

Authors:  Kenneth L Kehl; Wenxin Xu; Eva Lepisto; Haitham Elmarakeby; Michael J Hassett; Eliezer M Van Allen; Bruce E Johnson; Deborah Schrag
Journal:  JCO Clin Cancer Inform       Date:  2020-08

8.  Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.

Authors:  Tommy Mullaney; Xiang Zhou; Jane J Liu; Kristin L Ayers; Kyeryoung Lee; Meng Ma; Scott Jones; Li Li; Arielle Redfern; Whitney Jappe; Zongzhi Liu; Howard Goldsweig; Kamlesh K Yadav; Nicholas Hahner; Matthew Dietz; Michelle Zimmerman; Tony Prentice; Scott Newman; Rajwanth Veluswamy; Juan Wisnivesky; Fred R Hirsch; William K Oh; Shuyu D Li; Eric E Schadt; Rong Chen
Journal:  Oncologist       Date:  2021-05-11

9.  Health screening, cardiometabolic disease and adverse health outcomes in individuals with severe mental illness.

Authors:  Robert Pearsall; Richard J Shaw; Gary McLean; Moira Connolly; Kate A Hughes; James G Boyle; John Park; Daniel J Smith; Daniel Mackay
Journal:  BJPsych Open       Date:  2019-11-08

10.  Stakeholder perspectives on addressing adverse events from adjuvant cancer therapy: A qualitative study.

Authors:  Syril D Pettit; Pamela Silberman; Kristen Hassmiller Lich; Rebecca A Kirch; Steven E Lipshultz; Randall Teal; Ethan Basch
Journal:  Cancer       Date:  2019-08-27       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.